56875-60-6

Usage

Uses

7-methoxynaphthalene-2-sulfonyl chloride is a useful research chemical.

Upstream product

• 135-55-7 7-hydroxynaphthalene-2-sulfonic acid sodium salt 
• 10026-13-8 phosphorus pentachloride 

Downstream Products

• 186551-92-8 7-methoxynaphthalene-2-sulfonic acid [1-(2-amino-5-cyanobenzyl)-2-oxo-pyrrolidin-3-(S)-yl]amide 
• 245761-11-9 {4-cyan0-2-[3-(7-methoxynaphthalen-2-ylsulfonylamino)-2-oxopyrrolidin-1-ylmethyl]phenoxy}acetic acid methyl ester 
• 245760-97-8 7-methoxynaphthalene-2-sulfonic acid [1-(2-amino-5-cyanobenzyl)-2-oxopyrrolidin-3-yl]methylamide 
• 186552-01-2 7-methoxynaphthalene-2-sulfonic acid [1-(3-benzhydrylidenylamino-5-cyanobenzyl)-2-oxopyrrolidin-3-yl]amide 
• 186550-73-2 7-methoxynaphthalene-2-sulfonic acid [1-(4-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl]amide 
• 247030-74-6 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(R)-yl]amide 
• 186550-31-2 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl]amide 
• 250645-15-9 7-Methoxy-naphthalene-2-sulfonic acid {(S)-1-[6-(benzhydrylidene-amino)-1-chloro-isoquinolin-7-ylmethyl]-2-oxo-pyrrolidin-3-yl}-amide 
• 245760-98-9 7-methoxynaphthalene-2-sulfonic acid {1-[5-cyano-2-hydroxybenzyl]-2-oxopyrrolidin-3-(S)-yl}amide 
• 245761-05-1 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyano-4-hydroxybenzyl)2-oxopyrrolidinyl-3-(S)-yl]amide 
• 186550-65-2 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl]methylamide 
• 186551-10-0 7-Methoxy-naphthalene-2-sulfonic acid [(S)-1-(3-cyano-benzyl)-2-oxo-pyrrolidin-3-yl]-ethyl-amide 
• 186549-27-9 RPR120844 
• 186547-01-3 3-[(R)-3-(7-Methoxy-naphthalene-2-sulfonylamino)-2-oxo-pyrrolidin-1-ylmethyl]-benzamidine 

Relevant academic research and scientific papers

Heterocyclic derivatives and their use as antithrombotic agents

The present invention relates to antithrombotic compounds comprising the group Q, Q having formula (I), wherein the substructure (i) is a structure selected from (a, b and c), wherein X is O or S; X′ being independently CH or N; and m is 0, 1, 2 or 3; wherein the group Q is bound through an oxygen atom or an optionally substituted nitrogen or carbon atom, or a pharmaceutically acceptable salt thereof or a prodrug thereof. The compounds of the invention are therapeutically active and in particular are antithrombotic agents.

Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa

The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(s)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K1 = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl2-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.

SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More especially, they are Factor Xa inhibitors. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

HETEROAROMATIC AND THIOHETEROAROMATIC SUBSTITUTED SULFONAMIDE THROMBIN INHIBITORS

Sulfonamide thrombin inhibitors are provided which have the structure STR1 including all stereoisomers thereof, wherein X is S or--CH 2--; m is 0, 1 or 2 when X is--S--or m is 0 when X is--CH. sub.2--; n is 1, 2 or 3; R 1 and R 2 are independently H, lower alkyl, cyclo-alkyl, aryl, heteroaryl or heteroarylalkyl, or R 1 and R 2 can be taken together with the N atom to which they are attached to form a 5-to 8-membered ring which may optionally contain an additional N, O or S atom in the ring; R. sup.3 is heteroaryl; and R 4 is alkyl, cycloalkyl, aryl, heteroaryl, quinolinyl or tetrahydroquinolinyl, and pharmaceutically acceptable salts thereof.

HETEROAROMATIC AMINE THROMBIN INHIBITORS

Sulfonamide thrombin inhibitors are provided which have the structure STR1 including all stereoisomers thereof, wherein n is 1, 2 or 3; m is 0, 1 or 2; R 1 and R 2 are independently H, lower alkyl, cycloalkyl, aryl, heteroaryl or heteroaryl-alkyl, or R 1 and R. sup.2 can be taken together with the N atom to which they are attached to form a 4-to 8-membered ring; R 3 is monocyclic heteroaryl; and R 4 is alkyl, cycloalkyl, aryl, heteroaryl, quinolinyl or tetrahydroquinolinyl, and pharmaceutically acceptable salts thereof.